Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.9%

1 terminated/withdrawn out of 17 trials

Success Rate

94.1%

+7.6% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

50%

8 of 16 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 1
11(64.7%)
Phase 2
5(29.4%)
Phase 3
1(5.9%)
17Total
Phase 1(11)
Phase 2(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT01913951Phase 1Completed

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Role: collaborator

NCT01893320Phase 1Completed

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Role: collaborator

NCT03338348Phase 2Completed

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Role: collaborator

NCT03037645Phase 1Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Role: lead

NCT01980056Phase 1Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Role: collaborator

NCT00252382Phase 2Completed

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Role: lead

NCT01191801Phase 3Completed

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML

Role: lead

NCT00298896Phase 2Completed

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Role: lead

NCT00541866Phase 1Completed

Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans

Role: lead

NCT00408603Phase 2Completed

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

Role: lead

NCT00607997Phase 2Completed

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Role: lead

NCT00446342Phase 1Completed

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Role: lead

NCT00519662Phase 1Completed

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

Role: lead

NCT00246662Phase 1Completed

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Role: lead

NCT00292864Phase 1Completed

Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors

Role: lead

NCT00091585Phase 1Completed

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Role: lead

NCT00094159Phase 1Completed

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Role: lead

All 17 trials loaded